vay736
mAbexperimental
Clinical trial activity
31 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
24
Phase 3
12
Phase 4
0
Earliest trial started Dec 1, 2010 (NCT02675803)
Timeline
Indications
Studied for
- Anemia, Hemolytic, Autoimmune · Phase 3
- Arthritis, Rheumatoid · Phase 2
- Hepatitis, Autoimmune · Phase 2/Phase 3
- Idiopathic Pulmonary Fibrosis · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lupus Erythematosus, Systemic · Phase 3
- Lupus Nephritis · Phase 3
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Multiple Sclerosis · Phase 2
- Pemphigus · Phase 2
- Scleroderma, Diffuse · Phase 2
- Sjogren's Syndrome · Phase 3
- Thrombocytopenia · Phase 3
Mechanism of action
Tumor necrosis factor receptor superfamily member 13C binding agent
Dual mechanism: BAFF-R blocker and depletes B-cells by antibody-dependent cytotoxicity.
TNFSF13B inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4594357 ↗
Also known as
- vay736
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07039422 | Phase 2 | Oct 3, 2025 | Novartis |
| NCT06711887 | Phase 3 | May 16, 2025 | Novartis |
| NCT06411639 | Phase 1 | Nov 25, 2024 | Novartis |
| NCT06470048 | Phase 2 | Oct 9, 2024 | Novartis |
| NCT06293365 | Phase 2 | Jul 2, 2024 | Novartis |
| NCT06133972 | Phase 3 | May 17, 2024 | Novartis |
| NCT05985915 | Phase 3 | Oct 27, 2023 | Novartis |
| NCT05885555 | Phase 2 | Aug 16, 2023 | Novartis |
| NCT05624749 | Phase 3 | Mar 7, 2023 | Novartis |
| NCT05639114 | Phase 3 | Mar 1, 2023 | Novartis |
| NCT05653219 | Phase 3 | Dec 30, 2022 | Novartis |
| NCT05653349 | Phase 3 | Dec 29, 2022 | Novartis |
| NCT05648968 | Phase 3 | Dec 12, 2022 | Novartis |
| NCT05349214 | Phase 3 | Aug 4, 2022 | Novartis |
| NCT05350072 | Phase 3 | Jul 28, 2022 | Novartis |
| NCT05126277 | Phase 3 | Mar 3, 2022 | Novartis |
| NCT05124925 | Phase 2 | Jan 26, 2022 | Novartis |
| NCT04903197 | Phase 1 | Nov 30, 2021 | Novartis |
| NCT03656562 | Phase 2 | Nov 2, 2018 | Novartis |
| NCT03574545 | Phase 1 | Oct 22, 2018 | Novartis |
Showing 20 of 31 trials
Page 1 / 2
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 31 | 31 | 4 | 2010 |
1 organizations
Page 1 / 1